ALK tyrosine kinase inhibitors (ALK-TKIs) have demonstrated significant efficacy in ALK-positive non-small cell lung cancer (NSCLC) and are widely utilized as first-line therapy. This evidence concerns the gene ALK and non-small cell lung carcinoma.